This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

MICHAEL DAVIDSON, MD
Department of Psychiatry, Box 1230 Mount Sinai Hospital One Gustave L. Levy Place New York, NY 10029

RENE S. KAHN, MD; KENNETH L. DAVIS, MD
New York, NY

Arch Gen Psychiatry. 1992;49(12):1000.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The study described in the letter by Volavka et al retrospectively examined pHVA concentrations in 28 schizophrenic subjects. This sample was "selected" from a larger sample of 176 schizophrenic patients who were assigned to three plasma levels of haloperidol for 6 weeks. The authors used the entry and treatmentresponse criteria described in our article.¹ Their finding, in contrast to ours, was that haloperidol did not differentially affect pHVA in responders and nonresponders to haloperidol treatment.

Although their results appear to contradict findings from others and from our group,² their study was limited in several methodologic respects. First, their minimum drugfree period was 3 days for oral medication and 1 month for depot neuroleptic treatment. It is therefore quite conceivable that baseline pHVA levels were still suppressed by previous neuroleptic treatment. Second, only one weekly pHV sample was taken instead of the two samples per week in our study. . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?